{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:01:32Z","timestamp":1784808092713,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Haiyan Fund, Harbin Medical University Cancer Hospital","award":["JJED2016\u204302"],"award-info":[{"award-number":["JJED2016\u204302"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Updates Surg"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The objective is to evaluate whether gastric cancer patients with peritoneal metastasis can benefit from surgery through a comprehensive analysis of different clinical factors and perioperative treatment methods. A total of 135 gastric cancer patients with peritoneal metastasis were treated with Hyperthermic intraperitoneal chemotherapy (HIPEC). Patients were divided into either training group (without surgery, <jats:italic>n<\/jats:italic>\u2009=\u200990) or test group (with surgery, <jats:italic>n<\/jats:italic>\u2009=\u200945). A nomogram was constructed based on significant prognostic factors. The patients were divided into high- and low-risk groups using a nomogram. Overall survival were then compared according to whether surgery was performed in both groups. Alpha-fetoprotein (AFP), complications, conversion chemotherapy, and postoperative chemotherapy were significantly associated with overall survival (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). A nomogram was constructed using the above four factors and validated using the test set. The area under the curve (AUC) of the model was 0.752 (95% CI 0.525\u2013978). In the group that did not undergo surgery, the median survival times for the high-risk and low-risk groups were 7 and 11\u00a0months, respectively. In the surgery group, the median survival times for the high-risk and low-risk groups were 11 and 19\u00a0months, respectively. The difference was statistically significant (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). The four-factor nomogram can accurately predict high-risk and low-risk populations. Our findings suggest that cytoreductive surgery combined with HIPEC can improve the survival time of patients in both groups.<\/jats:p>","DOI":"10.1007\/s13304-024-01989-y","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T21:01:34Z","timestamp":1728075694000},"page":"2663-2674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prediction of surgical benefit in gastric cancer patients with peritoneal metastasis treated with hyperthermic intraperitoneal chemotherapy"],"prefix":"10.1007","volume":"76","author":[{"given":"Shiyang","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhe","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiancheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeshen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xirui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"issue":"3","key":"1989_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"1989_CR2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","volume":"134","author":"W Cao","year":"2021","unstructured":"Cao W, Chen HD, Yu YW, Li N, Chen WQ (2021) Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 134(7):783\u2013791. https:\/\/doi.org\/10.1097\/CM9.0000000000001474. (Published 2021 Mar 17)","journal-title":"Chin Med J (Engl)"},{"issue":"10251","key":"1989_CR3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F (2020) Gastric cancer. Lancet 396(10251):635\u2013648. https:\/\/doi.org\/10.1016\/S0140-6736(20)31288-5","journal-title":"Lancet"},{"issue":"30","key":"1989_CR4","doi-asserted-by":"publisher","first-page":"6906","DOI":"10.3748\/wjg.v22.i30.6906","volume":"22","author":"Y Li","year":"2016","unstructured":"Li Y, Zhou YF, Liang H et al (2016) Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies. World J Gastroenterol 22(30):6906\u20136916. https:\/\/doi.org\/10.3748\/wjg.v22.i30.6906","journal-title":"World J Gastroenterol"},{"key":"1989_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.03.030","volume":"79","author":"J Desiderio","year":"2017","unstructured":"Desiderio J, Chao J, Melstrom L et al (2017) The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer 79:1\u201314. https:\/\/doi.org\/10.1016\/j.ejca.2017.03.030","journal-title":"Eur J Cancer"},{"issue":"6","key":"1989_CR6","doi-asserted-by":"publisher","first-page":"794","DOI":"10.21147\/j.issn.1000-9604.2020.06.12","volume":"32","author":"Z Lei","year":"2020","unstructured":"Lei Z, Wang J, Li Z et al (2020) Hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: a multicenter propensity score-matched cohort study. Chin J Cancer Res 32(6):794\u2013803. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2020.06.12","journal-title":"Chin J Cancer Res"},{"issue":"5","key":"1989_CR7","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1245\/s10434-018-07140-7","volume":"26","author":"TE Newhook","year":"2019","unstructured":"Newhook TE, Agnes A, Blum M et al (2019) Laparoscopic hyperthermic intraperitoneal chemotherapy is safe for patients with peritoneal metastases from gastric cancer and may lead to gastrectomy. Ann Surg Oncol 26(5):1394\u20131400. https:\/\/doi.org\/10.1245\/s10434-018-07140-7","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 1","key":"1989_CR8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s10120-016-0684-3","volume":"20","author":"H Ishigami","year":"2017","unstructured":"Ishigami H, Yamaguchi H, Yamashita H, Asakage M, Kitayama J (2017) Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer 20(Suppl 1):128\u2013134. https:\/\/doi.org\/10.1007\/s10120-016-0684-3","journal-title":"Gastric Cancer"},{"issue":"6","key":"1989_CR9","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1245\/s10434-015-5081-3","volume":"23","author":"CS Chia","year":"2016","unstructured":"Chia CS, You B, Decullier E et al (2016) Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann Surg Oncol 23(6):1971\u20131979. https:\/\/doi.org\/10.1245\/s10434-015-5081-3","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"1989_CR10","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","volume":"18","author":"XJ Yang","year":"2011","unstructured":"Yang XJ, Huang CQ, Suo T et al (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 18(6):1575\u20131581. https:\/\/doi.org\/10.1245\/s10434-011-1631-5","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"1989_CR11","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1245\/s10434-019-07450-4","volume":"26","author":"I Manzanedo","year":"2019","unstructured":"Manzanedo I, Pereira F, Rihuete Caro C et al (2019) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Ann Surg Oncol 26(8):2615\u20132621. https:\/\/doi.org\/10.1245\/s10434-019-07450-4","journal-title":"Ann Surg Oncol"},{"issue":"23","key":"1989_CR12","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"PE Bonnot","year":"2019","unstructured":"Bonnot PE, Piessen G, Kepenekian V et al (2019) Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol 37(23):2028\u20132040. https:\/\/doi.org\/10.1200\/JCO.18.01688","journal-title":"J Clin Oncol"},{"issue":"12","key":"1989_CR13","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1245\/s10434-016-5306-0","volume":"23","author":"T Boerner","year":"2016","unstructured":"Boerner T, Graichen A, Jeiter T et al (2016) CRS-HIPEC Prolongs survival but is not curative for patients with peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol 23(12):3972\u20133977. https:\/\/doi.org\/10.1245\/s10434-016-5306-0","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"1989_CR14","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3748\/wjg.v22.i3.1114","volume":"22","author":"RA Seshadri","year":"2016","unstructured":"Seshadri RA, Glehen O (2016) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol 22(3):1114\u20131130. https:\/\/doi.org\/10.3748\/wjg.v22.i3.1114","journal-title":"World J Gastroenterol"},{"issue":"3","key":"1989_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/annonc\/mdz001","volume":"30","author":"D Dong","year":"2019","unstructured":"Dong D, Tang L, Li ZY et al (2019) Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer. Ann Oncol 30(3):431\u2013438. https:\/\/doi.org\/10.1093\/annonc\/mdz001","journal-title":"Ann Oncol"},{"issue":"7","key":"1989_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2017.1087","volume":"152","author":"Y Jiang","year":"2017","unstructured":"Jiang Y, Li T, Liang X et al (2017) Association of adjuvant chemotherapy with survival in patients with stage II or III gastric cancer. JAMA Surg 152(7):e171087. https:\/\/doi.org\/10.1001\/jamasurg.2017.1087","journal-title":"JAMA Surg"},{"issue":"3","key":"1989_CR17","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, van Gestel YR, van Ramshorst B et al (2014) Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer 134(3):622\u2013628. https:\/\/doi.org\/10.1002\/ijc.28373","journal-title":"Int J Cancer"},{"issue":"3","key":"1989_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10120-021-01268-4","volume":"25","author":"A Agnes","year":"2022","unstructured":"Agnes A, Biondi A, Persiani R et al (2022) Development of the PERI-Gastric (PEritoneal Recurrence Index) and PERI-Gram (Peritoneal Recurrence Index NomoGRAM) for predicting the risk of metachronous peritoneal carcinomatosis after gastrectomy with curative intent for gastric cancer. Gastric Cancer 25(3):629\u2013639. https:\/\/doi.org\/10.1007\/s10120-021-01268-4","journal-title":"Gastric Cancer"}],"container-title":["Updates in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-024-01989-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13304-024-01989-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-024-01989-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T14:11:44Z","timestamp":1732716704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13304-024-01989-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1989"],"URL":"https:\/\/doi.org\/10.1007\/s13304-024-01989-y","relation":{},"ISSN":["2038-131X","2038-3312"],"issn-type":[{"value":"2038-131X","type":"print"},{"value":"2038-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"10 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted with approval from the Ethics Committee of Harbin Medical University Cancer Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"The protocol for this research project conforms to the provisions of the Declaration of Helsinki. All informed consent\nwas obtained from the subject(s) and\/or guardian(s). This study is a retrospective study. The investigators treated patients with the treatment options recommended by the latest guidelines. The patient's treatment protocol was not intervened. The contents of the paper are observational results. All patients have signed informed consent for the use of clinical data before treatment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals, and Informed consent"}}]}}